Proteovista
Private Company
Funding information not available
Overview
Proteovista is a private, early-stage biotech focused on enabling precision drug discovery through its novel SNAP technology platform. The core innovation is a high-throughput microarray that profiles the binding affinity and specificity of proteins to millions of DNA sequences, complemented by a proprietary visualization tool. The company operates a hybrid business model, offering custom research services to generate revenue while advancing its own platform applications for discovering DNA-targeted small molecule therapeutics in oncology and cardiology. It is primarily grant-funded, as evidenced by awards from the National Cancer Institute.
Technology Platform
SNAP (Specificity and Affinity for Protein) microarray platform and Sequence Specificity Landscape (SSL) visualization tool for high-throughput profiling of protein-DNA binding affinity and specificity.
Opportunities
Risk Factors
Competitive Landscape
Proteovista competes with providers of protein-binding microarrays (e.g., from companies like Agilent, Roche NimbleGen) and other in vitro binding assays (SELEX, EMSA). In the drug discovery space, it faces competition from larger biopharma and biotech companies developing transcription factor inhibitors using various modalities. Its key differentiator is the combined high-throughput experimental platform and proprietary bioinformatics for visualizing sequence specificity landscapes.